Pharmacology
Mechanism of action
Zaleplon is a high-affinity ligand of positive modulator sites of GABAA receptors, which enhances GABAergic inhibition of neurotransmission in the central nervous system. The ultrashort half-life gives zaleplon a unique advantage over other hypnotics because of its lack of next-day residual effects on driving and other performance-related skills. Unlike nonselective benzodiazepine drugs and zopiclone, which distort the sleep pattern, zaleplon appears to induce sleep without disrupting the natural sleep architecture.A meta-analysis of randomized, controlled clinical trials which compared benzodiazepines against zaleplon or other Z-drugs such as zolpidem, zopiclone, and eszopiclone has found few clear and consistent differences between zaleplon and the benzodiazepines in terms of sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse events, tolerance, rebound insomnia, and daytime alertness.Zaleplon has a pharmacological profile similar to benzodiazepines, characterized by an increase in slow wave deep sleep (SWDS) with rapid onset of hypnotic action. Zaleplon is a full agonist for the benzodiazepine α1 receptor located on the GABAA receptor complex in the body, with lower affinity for the α2 and α3 subsites. It selectively enhances the action of GABA similar to, but more selectively than benzodiazepines. Zaleplon, although not a benzodiazepine, maintains a very similar pharmacological profile nonetheless, known for inducing hypnotic effects by α1 subreceptor sites, anxiolytic and muscle relaxant effects via α2 and α3 subsites, with negligible anticonvulsant properties (via α5 subsite), as zaleplon action is modulated at benzodiazepine receptor sites. The elimination half-life of zaleplon is about 1–1.5 hours.
Kumar, Rajesh S.; Baskaran, Mani; Chew, Paul T.K. ; Friedman, David S.; Handa, Swati; Lavanya, Raghavan; Sakata, Lisandro M.; Wong, Hon-Tym; Aung, Tin (March 2008). "Prevalence of Plateau Iris in Primary Angle Closure Suspects". Ophthalmology. 115 (3): 430–434. doi:10.1016/j.ophtha.2007.07.026. PMID 17900691. Kumar, Rajesh S.; Tantisevi, Visanee; Wong, Melissa H.; Laohapojanart, Kobkuea; Chansanti, Orathai; Quek, Desmond T.; Koh, Victor T.; MohanRam, Lakshmana S.; Lee, Kelvin Y.; Rojanapongpun, Prin; Aung, Tin (12 October 2009). "Plateau Iris in Asian Subjects With Primary Angle Closure Glaucoma". Archives of Ophthalmology. 127 (10): 1269–1272. doi:10.1001/archophthalmol.2009.241. PMID 19822841. Viet Tran, H; Liebmann, Jeffrey M; Ritch, Robert (January 2003). "Iridociliary apposition in plateau iris syndrome persists after cataract extraction". American Journal of Ophthalmology. 135 (1): 40–43. doi:10.1016/S0002-9394(02)01842-1. PMID 12504695. Pavlin, Charles J; Foster, F.Stuart (September 1999). "Plateau iris syndrome: changes in angle opening associated with dark, light, and pilocarpine administration". American Journal of Ophthalmology. 128 (3): 288–291. doi:10.1016/s0002-9394(99)00149-x. PMID 10511021.